<p><strong>Atlas Brown, Inc.</strong> Adjusts Portfolio in Q3 2026: Focus on Fixed Income and Technology</p>

In the third quarter of 2026, Atlas Brown, Inc. managed its investment portfolio with a mix of strategic adjustments, reflecting shifts in its investment strategy and market outlook. The firm's portfolio, valued at approximately $379.16 million as of September 30, 2026, includes a diverse range of holdings across multiple sectors, with a notable emphasis on Technology and Healthcare stocks, as well as fixed income instruments.

Among the top holdings, NVIDIA Corporation (NVDA) saw a slight reduction in Atlas Brown's stake, with a decrease of 617 shares, representing a 0.49% change from the previous quarter. Similarly, Apple Inc. (AAPL) experienced a small decline in its position, with a decrease of 612 shares and a -0.91% change. Microsoft Corporation (MSFT) also saw a minor reduction in holdings, with a decrease of 64 shares and a -0.27% change. On the other hand, Johnson & Johnson (JNJ) and Pfizer Inc. (PFE) maintained their positions with minimal changes, while JPMorgan Chase & Co. (JPM) also saw a slight decrease.

Atlas Brown, Inc. demonstrated a clear focus on fixed income investments during Q3 2026. The firm significantly increased its position in iShares Core Total U.S. Bond Market ETF (IUSB), adding 4,820 shares, which boosted its portfolio allocation to 0.16%. Similarly, the firm made a substantial purchase of JBS N.V. (JBS) shares, acquiring 14,860 new shares, pushing its allocation to 0.07%. The increase in JBS was particularly notable, with a 148.6% change from the prior period. Additionally, the firm added a new position in iShares U.S. Treasury Bond ETF (GOVT), investing in 11,214 shares, which now accounts for 0.06% of the portfolio.

In the Technology sector, Atlas Brown, Inc. also showed interest in smaller technology-related holdings. The firm added a position in Uber Technologies Inc. (UBER), investing in 10,120 shares, increasing its allocation to 0.18%. This suggests a continued interest in innovative tech companies, albeit on a smaller scale compared to its core Technology holdings. The firm also increased its stake in Novo Nordisk A/S ADR (NVO) by 7,357 shares, a 100% increase, though this is a relatively small holding at 0.07%.

Healthcare sector saw moderate changes, with Abbott Laboratories (ABT) experiencing a slight increase in shares (+0.19%) and a small addition in holdings. However, the firm sold its position in Coro Group (CORO) ETF, exiting the position entirely, which was a 100% change from the prior period. This exit might indicate a shift in strategy or a lack of further interest in the country rotation strategy of that ETF.

Consumer-focused holdings also saw activity. Wendy's Co. (WEN) experienced a significant increase, with the addition of 10,000 shares, boosting its allocation to 0.08%. This is a substantial increase of 28.57% in the position. Conversely, the firm sold its position in RPM International Inc. (RPM), exiting the holding completely, which was a -46.3% change from the prior period.

Overall, Atlas Brown, Inc.'s portfolio adjustments in Q3 2026 reflect a strategic move towards fixed income and select consumer/healthcare names, while maintaining a core focus on Technology and Healthcare stocks. The significant increase in fixed income allocation suggests a potential conservative stance or a tactical move in response to market conditions. The firm's actions in consumer sectors like JBS and WEN indicate targeted growth in specific areas, while the exit from CORO and RPM suggests a more selective approach to certain sectors.